These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Expression of CCDC67 mRNA and its role in patients with papillary thyroid carcinoma].
    Author: Yin D, Xu J, Wang Y, Li H, Zhang Y, Jiang J, Wang Q.
    Journal: Zhonghua Yi Xue Za Zhi; 2014 Aug 13; 94(30):2382-5. PubMed ID: 25399985.
    Abstract:
    OBJECTIVE: To explore the expression of CCDC67 mRNA between papillary thyroid carcinoma (PTC) and adjacent normal tissues. METHODS: Reverse transcription-polymerase chain reaction (RT-PCR) was employed to detect the expression of CCDC67 mRNA in 48 cases of papillary thyroid carcinoma and their matched adjacent non-cancerous epithelium and cell lines of thyroid carcinoma. RESULTS: There was no expression of CCDC67 mRNA in SW579 and TPC-1 cell line. All cases had the expression of CCDC67 in adjacent normal tissues while the expression of CCDC67 mRNA was down-regulated significantly, only 39.6% (19/48) in 48 cases of thyroid carcinoma. In PTC, the expression rates of CCDC67 mRNA in stage I-II and III-IV were 60% (12/20) and 25% (7/28) and 24.1% (7/29) and 63.2% (12/19) in the lymph node metastasis and non-metastasis groups respectively. Also the expression rates of CCDC67 mRNA in Grades I and II were 61.1% (11/18) and 26.7% (8/30) respectively. And there was significant difference between two groups (P < 0.05). CONCLUSIONS: The down-regulated expression of CCDC67 is one of reasons for inactivation of PTC. And it may play an important role in carcinogenesis and progression of PTC.
    [Abstract] [Full Text] [Related] [New Search]